| Dr Maria Sklavos Servinsky, OD | |
|
17001 Science Dr, Suite 120, Bowie, MD 20715-4329 | |
| (301) 860-7090 | |
| Not Available |
| Full Name | Dr Maria Sklavos Servinsky |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 20 Years |
| Location | 17001 Science Dr, Bowie, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710083258 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TA1891 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Paul A Tarantino, M.d.,p.a. | 5991788127 | 4 |
| Joanne Brilliant O.d., P.a. | 7911976725 | 3 |
News Archive
There are socioeconomic differences in Sweden in survival amongst people with malignant skin melanoma, according to a study published in the European Journal of Cancer.
De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound's risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule's journey to market.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.
› Verified 5 days ago
| Provider Name | Paul A Tarantino, M.d.,p.a. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1821005059 PECOS PAC ID: 5991788127 Enrollment ID: O20040609001162 |
News Archive
There are socioeconomic differences in Sweden in survival amongst people with malignant skin melanoma, according to a study published in the European Journal of Cancer.
De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound's risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule's journey to market.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.
› Verified 5 days ago
| Provider Name | Joanne Brilliant O.d., P.a. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1144403098 PECOS PAC ID: 7911976725 Enrollment ID: O20040929000069 |
News Archive
There are socioeconomic differences in Sweden in survival amongst people with malignant skin melanoma, according to a study published in the European Journal of Cancer.
De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound's risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule's journey to market.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.
› Verified 5 days ago
| Provider Name | The Glaucoma Center, P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508921792 PECOS PAC ID: 2668430364 Enrollment ID: O20050404000455 |
News Archive
There are socioeconomic differences in Sweden in survival amongst people with malignant skin melanoma, according to a study published in the European Journal of Cancer.
De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound's risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule's journey to market.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maria Sklavos Servinsky, OD 17001 Science Dr Ste 120, Bowie, MD 20715-4330 Ph: (301) 860-1090 | Dr Maria Sklavos Servinsky, OD 17001 Science Dr, Suite 120, Bowie, MD 20715-4329 Ph: (301) 860-7090 |
News Archive
There are socioeconomic differences in Sweden in survival amongst people with malignant skin melanoma, according to a study published in the European Journal of Cancer.
De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound's risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule's journey to market.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.
› Verified 5 days ago
Dr. Carmoly T Sanders, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4412 Mitchellville Rd, Bowie, MD 20716 Phone: 301-809-0000 Fax: 301-809-6004 | |
Dr. Shelley Dorae Woody, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4412 Mitchellville Rd, Bowie, MD 20716 Phone: 301-809-0000 Fax: 301-809-0000 | |
Dr. Richard Arthur Miller Jr., O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 15616 Emerald Way, Bowie, MD 20716 Phone: 301-860-1802 | |
Bowie Optometric Group Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3327 Superior Ln, 206 &207, Bowie, MD 20715 Phone: 301-262-1210 Fax: 301-352-3568 | |
Myeyedr. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6800 Laurel Bowie Rd, Bowie, MD 20715 Phone: 301-464-4442 Fax: 301-464-2554 | |
Premier Eye Care Center Llc Optometrist Medicare: Medicare Enrolled Practice Location: 12164 Central Ave Ste 220, Bowie, MD 20721 Phone: 301-218-1862 | |
Dr. Cerina Leigh Buchanan, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6804 Race Track Rd, Bowie, MD 20715 Phone: 301-262-1210 Fax: 301-352-3568 |